How long can crizotinib be used?

The maximum length of time crizotinib can be used is a complex question because it is affected by many factors, including the patient's condition, physical condition, development of drug resistance, and doctor's treatment recommendations.

Crizotinib, as an ALK gene inhibitor, has significant efficacy in patients with ALK gene-positive locally advanced or metastatic non-small cell lung cancer. In clinical studies, up to 85.7% of patients can achieve clinical remission after using crizotinib, and the progression-free survival period is as long as 19.3 months. In addition, 50% of patients can survive longer than 51.4 months. These data suggest that for a subset of patients, crizotinib can provide prolonged treatment benefits.

The duration of use of crizotinib is limited by drug resistance. Research data shows that the median resistance period of crizotinib is 5 months, which means that after a period of time, some patients may develop resistance to the drug, causing the drug to be less effective or ineffective. Despite this, some patients have been able to use crizotinib for about 2 years.

It's important to note that each patient's situation is unique. The duration of crizotinib use varies between individuals and depends on factors such as the malignancy of the tumor, whether metastasis occurs, the patient's physical condition, and response to the drug. Therefore, the doctor will develop a personalized treatment plan based on the patient's specific situation, and may make adjustments according to changes in the condition during the treatment process.

In order to prolong the use time of crizotinib and improve the therapeutic effect, doctors may recommend that patients cooperate with other methods such as radiation therapy and chemotherapy to control the development of tumors. In addition, for patients who develop drug resistance, doctors may recommend re-examination of genetic tests and replacement of other appropriate targeted drugs for treatment.